Logo

CHEK

Check-Cap Ltd.

CHEK

Check-Cap Ltd. • NASDAQ
$1.61 ▲ 1.90% (+0.03)
Market Cap $9.42 M
52w High $3.13
52w Low $0.56
Dividend Yield 0%
P/E -0.37
Volume 42.15K
Outstanding Shares 5.85M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $0 $9.565M $-9.418M 0% $-1.61 $-1.254M
Q3-2024 $0 $9.565M ▲ $-9.418M ▼ 0% $-1.61 ▼ $-1.254M ▲
Q2-2024 $0 $3.409M $-3.156M 0% $-0.54 $-3.397M
Q1-2024 $0 $3.409M ▼ $-3.156M ▲ 0% $-0.54 ▲ $-3.397M ▲
Q4-2023 $0 $4.063M $-3.658M 0% $-0.63 $-3.757M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $265K $377K $1.827M $-1.45M
Q3-2024 $265K ▼ $377K ▼ $1.827M ▲ $-1.45M ▼
Q2-2024 $17.824M $18.09M $913K $17.177M
Q1-2024 $17.824M ▼ $18.09M ▼ $913K ▼ $17.177M ▼
Q4-2023 $24.756M $25.017M $1.33M $23.687M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-9.418K $-536 $-8.376K $0 $0 $-536
Q3-2024 $-9.418K ▼ $-536 ▲ $-8.376K ▼ $0 $0 $-536 ▲
Q2-2024 $-3.156K $-3.466K $7.956K $0 $0 ▲ $-3.466K
Q1-2024 $-3.156K ▲ $-3.466K ▲ $7.956K ▼ $0 $-8.844K ▼ $-3.466K ▲
Q4-2023 $-3.658M $-3.539M $8.87M $0 $5.331M $-3.539M

Five-Year Company Overview

Income Statement

Income Statement The company has effectively had no product sales for years, so its income statement is dominated by operating expenses and persistent losses. Those losses have been fairly steady over time rather than exploding higher, but there has been no sign of revenue traction to offset them. Earnings per share look very negative largely because of repeated reverse splits, which shrink the share count and magnify the loss per share on paper. Overall, the historical income picture is that of a development-stage company that never made it to commercial scale before pivoting strategies.

Balance Sheet

Balance Sheet The balance sheet has steadily shrunk, with total assets and shareholders’ equity drifting down to very low levels. There is no financial debt, which removes one source of pressure, but that is offset by the simple fact that the company now appears to have very limited resources of any kind. Over time, cash and other assets were used to fund operations, with little coming back in the form of new productive assets. The current balance sheet looks more like a corporate shell waiting for a new business to be injected than an operating medical company with substantial infrastructure.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting ongoing spending on development and overhead without any offsetting inflows from customers. Capital spending has been minimal, so cash burn is almost entirely driven by payroll, R&D, and administrative costs. Historically, this kind of profile implies reliance on external funding, such as equity raises, to keep going. With cash now effectively exhausted in the reported figures, the sustainability of the legacy business on its own looks very limited, which helps explain the strategic decision to merge and pivot.

Competitive Edge

Competitive Edge As a medical diagnostics company, Check-Cap’s potential moat rested on its unique, prep-free colon screening capsule. That idea was differentiated but ultimately stumbled on clinical and regulatory performance, weakening its competitive position and preventing it from turning its technology into a commercial franchise. With the merger, the story moves into a very different arena: embodied AI and robotics orchestration. In that new space, the company aims to compete on software intelligence, hardware-agnostic integration, and enterprise-scale deployments. This field is promising but crowded, with many well-funded technology and automation players. Any future moat will depend on how effectively MBody AI’s platform can become embedded with large customers and robot manufacturers, and whether it can move fast enough to stand out in a rapidly evolving AI landscape.

Innovation and R&D

Innovation and R&D Historically, Check-Cap was an R&D-heavy medtech developer, investing mainly in its C-Scan capsule and related systems. That program represented a meaningful technical innovation in patient comfort but did not reach the performance thresholds needed for full commercialization, which ultimately capped the return on that R&D. The new direction, via MBody AI, shifts innovation toward software, machine learning, and robotics coordination. Here, value will come from improving algorithms, scaling deployments, and adapting the platform to multiple industries. This is a more flexible, software-centric R&D model but also highly competitive and dependent on constant innovation to avoid being leapfrogged by other AI and automation providers.

Summary

Check-Cap’s historical financials describe a pre-revenue, development-stage medical company that never transitioned to a sustainable commercial model: no sales, steady operating losses, a shrinking asset base, and repeated reverse splits. The balance sheet and cash flows now look more like those of a nearly exhausted shell than a going, standalone healthcare business. In response, the company has chosen a transformational path: merging with MBody AI and effectively reinventing itself as an embodied AI and robotics orchestration company. This creates a clean break between the weak legacy economics and a new, higher-growth but much more competitive technology field. Going forward, the story hinges less on the old medical project and more on whether the combined entity can execute on AI-driven automation at scale, win and retain large enterprise customers, and build a durable position in a fast-moving market. The opportunity is significant but comes with high execution and strategic risk, typical of a full business model pivot.

NEWS

November 17, 2025 · 8:35 AM UTC

MBody AI ($CHEK) Secures 98% Shareholder Approval to Become Leading Nasdaq Embodied AI Company

Read more

November 10, 2025 · 8:35 AM UTC

MBody AI ($CHEK) Expands Global Leadership in Embodied AI With Major Wins

Read more

November 6, 2025 · 8:01 AM UTC

RETRANSMISSION: Check-Cap and MBody AI Advance Toward Closing Transformational Merger

Read more